Please provide your email address to receive an email when new articles are posted on . WASHINGTON — An expert panel of physicians, researchers and scientific advisers called upon The Liver Meeting ...
Please provide your email address to receive an email when new articles are posted on . Among 133,732 veterans with HCV, 80.1% initiated treatment and 91.6% achieved SVR. Younger veterans were less ...
As described in a recent JAMA Viewpoint, the proposed national HCV elimination program intends to engage underserved populations in need of HCV treatment by working closely with grassroots ...
Atea Pharmaceuticals (NASDAQ:AVIR) used its presentation at the 44th Annual JPMorgan Healthcare Conference to provide updates ...
C-FORWARD is the Second Phase 3 Trial in the Global HCV Development Program; the First Phase 3 Trial, C-BEYOND, is Currently Enrolling Patients in the US and Canada Regimen has Potential Best-in-Class ...
Management reiterated guidance that patient enrollment for the C-BEYOND trial will complete next month with top line results anticipated in mid-2026. Enrollment for C-FORWARD is expected to finish mid ...
Pills can cure infection with the hepatitis C virus (HCV), but getting the medication to patients who need treatment can be a challenge. Many patients with HCV use drugs such as methamphetamine or ...
Advances in treatment for hepatitis C virus (HCV) have the potential to generate considerable spillover benefits to patients awaiting transplants, especially among those with non—HCV-mediated liver ...
Atea Pharmaceuticals announced the ongoing enrollment in its Phase 3 C-BEYOND trial evaluating the combination of bemnifosbuvir and ruzasvir for the treatment of hepatitis C virus (HCV). Positive ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results